Twist Bioscience (NASDAQ:TWST) Trading Up 3.5% - Time to Buy?

Shares of Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) shot up 3.5% on Friday . The stock traded as high as $29.79 and last traded at $29.90. 209,914 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 1,094,475 shares. The stock had previously closed at $28.89.

Analyst Ratings Changes

Several equities analysts recently commented on TWST shares. Barclays dropped their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group dropped their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Robert W. Baird lowered their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Finally, Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus target price of $50.40.

Twist Bioscience Stock Performance

The company has a market capitalization of $1.86 billion, a PE ratio of -9.19 and a beta of 2.54. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The business's fifty day moving average is $35.28 and its two-hundred day moving average is $42.29.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million for the quarter, compared to analysts' expectations of $92.00 million. Equities research analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Activity

In other Twist Bioscience news, insider Dennis Cho sold 689 shares of the business's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $25,940.85. Following the completion of the sale, the insider now directly owns 110,849 shares in the company, valued at $4,173,464.85. The trade was a 0.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Paula Green sold 918 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the transaction, the senior vice president now directly owns 130,912 shares in the company, valued at approximately $5,355,609.92. This represents a 0.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,850 shares of company stock valued at $974,764 over the last three months. Insiders own 3.01% of the company's stock.

Institutional Trading of Twist Bioscience

Several institutional investors and hedge funds have recently modified their holdings of TWST. Barclays PLC grew its holdings in Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after buying an additional 104,420 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Twist Bioscience by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after acquiring an additional 189,791 shares during the last quarter. Wells Fargo & Company MN grew its position in Twist Bioscience by 34.5% in the fourth quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock worth $1,761,000 after acquiring an additional 9,722 shares in the last quarter. KBC Group NV grew its position in Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after acquiring an additional 1,226 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its position in Twist Bioscience by 18.9% during the fourth quarter. Teacher Retirement System of Texas now owns 17,357 shares of the company's stock valued at $807,000 after purchasing an additional 2,755 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.